Stay updated with breaking news from Presentation Time. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic activity of AB-101 against tumor cells and... | June 9, 2023
A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic...
SAR'579/IPH6101, ANKET platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by
LEXINGTON, Mass., May 04, 2023 -- Keros Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients... | May 4, 2023
/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...